Latest information on COVID-19

Our Vision

Despite a growing armamentarium, there is still a lack of treatment options available for end-stage heart failure (ESHF) patients. With cardiac transplantation considered the only real cure for end-stage heart disease, the need for more viable and accessible therapies is increasing.

The Shudo laboratory strives to develop novel tissue engineering strategies, such as bioengineering, biomechanical, and biostatistical approaches to treat ESHF. We hope this research can be successfully translated to the clinical arena to positively impact progression to heart failure following myocardial infarction.

Moreover, our clinical focus is on the surgical treatment for ESHF, with a particular emphasis on the outcome of the orthotopic heart transplant, heart-lung transplant, and mechanical circulatory support (MCS), including extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD).

In our unique interdisciplinary and collaborative research, from bench molecular and cellular biology through tissue engineering to bedside surgery, we envision a better quality of life for heart failure patients.